(via Thenewswire.ca)

Vancouver, British Colu mbia / TNW-ACCESSWIRE / October 2, 2014 / Vodis Pharmaceuticals Inc. (the "Company" or "Vodis") (CSE: VP / FSE: 1JV) ) is pleased to announce that the Company has formed a Washington State-based wholly owned subsidiary, Vodis USA, Inc., to invest in and develop real estate in Washington State for the purpose of serving licensed I-502 production and processing businesses. Vodis USA, Inc. intends to acquire real estate, retrofit buildings and provide production ready facilities to qualified I-502 cannabis tier 3 production and processing license holders.

In addition to providing specialized facilities to I-502 producers and processors, the Company will license its award winning, pharmaceutical grade growing techniques, standard operating procedures and innovative manufacturing practices to further assist license holders with their production and processing operations. The Company believes these services will create synergies and advantages that will provide for significant and long-term revenue for the license holder and, in turn, to Vodis USA, Inc.

ABOUT THE WASHINGTON I-502 MARIJUANA MARKET

In November, 2012, the Washington State Liquor Control Board (WSLCB) passed Initiative 502 (I-502) pursuant to a vote by the people of the State of Washington. I-502 authorized the WSLCB to regulate and tax recreational marijuana products for persons over twenty-one years of age and thereby, created a new industry for the growing, processing and selling of Washington State-regulated recreational marijuana products. A recent WSLCB commissioned report by the Rand organization suggests that there are currently up to 650,000 recreational marijuana users in Washington State worth approximately $1.25 - $1.5 Billion USD in annual sales.

ABOUT VODIS PHARMACEUTICALS

Vodis is one of Canada's foremost brand names in the medical marijuana business. Its master grow teams have consistently won or placed at each competition they have entered. The company is awaiting a Health Canada inspection to begin production at its state-of-the-art 12,000 square foot facility in Canada, which will have a theoretical capacity of up to 200 pounds per month or up to $8.7 million in annual revenue.

For further information please contact:

Brian Gusko

CFO & Director

Vodis Pharmaceuticals

104-1037 West Broadway

Vancouver, BC V6H 1E3

direct: 1-866-210-1420 ext. 106

web: www.vodis.ca

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Forward-Looking Information:

This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions, and include that our subsidiary plans to acquire real estate, retrofit buildings and provide production ready facilities to i-502 cannabis production licensees; that our operating procedures and innovative manufacturing practices can ensure the success of the licensee's production, which will provide for long-term revenue; and that we are only waiting for a Health Canada inspection to begin production at our 12,000 square foot facility, which will have a theoretical capacity of up to 200 pounds per month or up to $8.7 million in annual revenue . Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. Factors which could delay or prevent these forward looking statements from coming to fruition include that we don't get regulatory approval for establishment of US operations; that we are prohibited because of Washington State law from providing the kind of services we envision to growers; that we don't find any suitable real estate to acquire; that we lack the financing to carry out our plans or our operations; that we lost key employees whose knowledge is crucial for our operations; that we are turned down for a license to grow in Canada; that zoning laws don't permit us to carry out our plans; that our theories of growing capacity or revenues are not realistic as a result of miscalculation or changing markets. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting any person to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About PRC Partners

PRC Partners is a Hong Kong-based corporate development consulting firm owned Frank Haentjes. Mr. Haentjes is a native of Cologne, Germany, who was raised and educated in Brazil, Germany and the United States. He has been living and working in China for much of the last decade, successfully assisting Canadian public companies in tapping investment funds from state-owned enterprises and high-net-worth individuals.

PRC Partners has a self-professed focus on the discovery of undervalued and promising growth companies, and serves these companies by increasing visibility and accessing capital through an experienced network of investors. He has extensive relationships in Asia, Europe and the Middle East. He will be providing the services on behalf of PRC Partners.

We seek Safe Harbor.

For further information please contact:

Brian Gusko

CFO & Director

Vodis Pharmaceuticals

104-1037 West Broadway

Vancouver, BC V6H 1E3

direct: 1-866-210-1420 ext. 106

web: www.vodis.ca

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Forward-Looking Information:

responsibility for the adequacy or accuracy hereof.

This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. All of the forward-looking statements made in this news release and any accompanying graphic links are qualified by these cautionary statements and those in our continuous disclosure filings available on SEDAR at www.sedar.com. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

This news release, required by applicable Canadian laws, is not for distribution to U.S. news services or for dissemination in the United States and does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

Copyright (c) 2014 TheNewswire - All rights reserved.